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1. Introduction
1.1. The centennial history of Hashimoto’s thyroiditis
One hundred years ago, a 31-year old Japanese surgeon called Hakaru Hashimoto at Kyoto
Imperial University published the description of four cases of goiter in the thyroid resection
specimens from four women in a German journal Archiv für Klinische Chirurgie in 1912 just
before World War I. This paper contained two Latin words in the title (struma lymphomatosa)
and five microphotographs. The histological appearance of these goiters characterized by a
lymphoplasmocytic infiltrate with diffuse inflammatory alterations of the thyroid parenchyma
and fibrosis was very different from the colloid goiters that he was familiar with, as well as
those from Grave’s disease, infectious thyroiditis (especially related to tuberculosis or syphilis)
and the fibrous thyroiditis described by Riedel in 1896. He emphasized similarity with the
histological data observed with lacrimal, salivary, lymph node and splenic involvement of
Mikulicz’s disease (now Sjögren's syndrome). Mickulicz was the teacher of Hayari Miyake,
the head of Hashimoto’s department.
The four observed cases involved female patients over the age of 40 years who had formed
very firm diffuse goiters, to the extent that the diagnoses were suggestive of fibrous thyroid
or cancer at that time. But these were isolated, with hardly any severe signs of compression
and no adenopathy. The postoperative course of these goiters seemed more complicated than
usual. One case was complicated by recurrence, soon followed by spontaneous reduction of
the hypertrophy.
Hashimoto decided to continue his training in Göttingen, Germany and then in England. He
was forced to return home after the outbreak of World War I. He continued to practice as a
general practitioner in rural Midai in 1916 and died in 1934 at the age of 52 years from typhoid
contracted from a patient, without achieving the recognition he deserved.
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Hashimoto’s discovery was not exactly ignored for the next few decades, but recognition of
its existence was certainly slow, possibly related in part to the publication of the paper in
German. In 1931, Graham and McCullagh used the term ‘‘Hashimoto’’ for the first time in the
title of an article, strongly arguing that struma lymphomatosa was indeed distinct from
Riedel’s thyroiditis. The description of lymphocytic thyroiditis was rediscovered in the United
States in 1936, and the disease was labeled Hashimoto’s thyroiditis (chronic lymphocytic
thyroiditis) in medical textbooks. In 1939, the prominent British thyroid surgeon Cecil Joll
coined the term ‘‘Hashimoto disease’’ and used it in the title of a review he wrote about this
condition. Since then, Hashimoto’s thyroiditis has gone from being a rarity to one of the most
common autoimmune diseases, as well as the most common endocrine disease.
An essential step was the characterization in 1956 by Noel Rose and Ernest Witebsky of
experimental thyroiditis created by the injection of thyroid extracts and Freund adjuvant in
rabbits, which showed histological aspects similar to those described by Hashimoto. In the
same year, Ivan Roitt and Deborah Doniach reported the presence of autoantibodies directed
against thyroglobulin in the Lancet. Until then it had seemed inconceivable that an individual
would develop antibodies directed against his own body (‘‘horror autotoxicus’’). This was the
first time that the possibility of autoimmune diseases had been suggested, and Hashimoto’s
disease established itself as the model of organ-specific autoimmune diseases. It is a good
example of a situation in which a brilliant clinician provided the clinical and anatomopatho‐
logical description of a disease, leaving it to future generations to understand the mechanism
and, in the current case, to establish the far-reaching concept of autoimmune diseases,
sometimes organ-specific, polyglandular or general.
With regard to history, there is agreement that the hypertrophic forms of lymphocytic
thyroiditis, which can progress to atrophy although not inevitable, would be labeled Hashi‐
moto’s thyroiditis. In terms of the pathogenic, histologic and biologic perspectives, these forms
did not differ greatly from atrophic lymphocytic thyroiditis causing myxoedema, or asymp‐
tomatic autoimmune thyroiditis or thyroiditis occurring with nodules or cancer. These aspects
are the subject of the article by Orgiazzi. Even before the description of lymphocytic thyroiditis
by Hashimoto, the simultaneous occurrence of hypothyroidism with other endocrinopathies
had been demonstrated in Germany in 1904 by Erhlich, and in 1908 in France by Claude and
Gougerot. In 1980 these conditions of polyglandular failure were divided into four types by
Neufeld, and then grouped into two varieties. Childhood-onset type 1 autoimmune polyen‐
docrine syndrome has autosomal recessive transmission linked to a mutation of the AIRE gene,
which controls the production of antibodies at the thymic and peripheral levels. This can be
differentiated from type 2 (or 2/3), which is much more frequent, starts in adulthood, and is
polygenic and multifactorial, the characteristics of which are presented by Kahaly. Whether
isolated or occurring with polyendocrinopathies, autoimmune involvement of the adrenal
glands alters the quality of life and is life-threatening; it is explained and its care are described
in the article by Napier and Pearce. The pathogenic access and assessment of autoimmune
involvement in parathyroid and pituitary are still in the early stages, while the immunologic
and pathogenic data and management perspectives are better understood in diabetes mellitus,
as confirmed in the article by Boitard. The description of the histological changes of Hashi‐
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moto’s thyroiditis, only just a century ago, gained credibility over several decades. Hashimo‐
to’s thyroiditis is now considered the most prevalent autoimmune disease.
2. Prevalence over time
Its incidence is about 1 case per 1000 persons per year. The prevalence is 8 cases per 1000 when
estimated from a review of published articles, and 46 cases per 1000 when estimated from the
biochemical evidence of hypothyroidism and thyroid autoantibodies in subjects participating
to the Third National Health and Nutrition Examination Survey. Caturegli(Caturegli, De
Remigis et al. 2013) and colleagues have marked the centenary of Hashimoto’s seminal paper
by reviewing the extensive surgical pathology archives of the Johns Hopkins Hospital for cases
of Hashimoto thyroiditis, spanning an extremely long period from 1889 to 2012. The results
are fascinating and a fitting way to mark this important anniversary. The study reveals a
remarkable change in incidence, with very few cases for the first half of the period, and then
a significant increase between 1943 and 1967, a constant incidence up to 1992 and then another
significant increase over the last two decades.
Of course this retrospective pathological analysis can take little account of the clinical reasons
for thyroid surgery, which will have a fundamental impact on the incidence, but the results
are so striking that a rapid increase in the frequency of Hashimoto’s thyroiditis in the second
half of the 20th century seems an unavoidable conclusion. Another review supported this by
reviewing of 1050 Austrians patients who had surgery for benign goiter between 1979 and
2009; there was a significant increase in the incidence of both lymphocytic thyroiditis and
Hashimoto’s thyroiditis in resection specimens over this time. In addition, a striking rise in
Hashimoto’s thyroiditis has been reported recently in Italy. Between 1975 and 2005, there was
a 10-fold rise in incidence: patients have become relatively younger, are more likely to be male,
and have lower autoantibody responses. While some of this change in incidence could be the
result of increased thyroid function testing and earlier detection of disease, the overwhelming
conclusion is that environmental factors must be responsible. Increased iodine intake is
certainly one possible influence: a recent study in China showing increases in subclinical
hypothyroidism and autoimmune thyroiditis in an area of more than adequate iodine intake
is the latest among many such reports. But not all studies have shown an adverse effect of
excess dietary iodine (possibly related to genetic factors and the rate of the increase in iodine
intake in a population) and when it does occur, the effect of iodine may be transient. Nor is
thyroid autoimmunity alone in this regard; celiac disease, type 1 diabetes, and multiple
sclerosis have all increased in incidence over the last three decades. It is likely that aspects of
urbanized living, such as higher standards of hygiene, increased prosperity, and increased
exposure to environmental toxins, are responsible for this generalized trend, perhaps by
altering the balance between T helper cell subtypes.
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3. Pathogenesis and etiology
The pathogenesis of Hashimoto’s thyroiditis has elicited interest since it was first reported. Dr.
Hashimoto himself speculated on possible explanations of what he saw under the microscope,
eventually concluding ‘‘at present we cannot say anything definite about the cause’’. Initial
theories postulated this disease was due to infection, understandably, since infections were
quite common and a large focus of clinical investigation, but no clear link with microorganisms
was ever found. Other theories considered the Hashimoto goiter a premalignant condition.
Some scholars believed the thyroid itself possessed a lymphogenic secretory capability that
became hyperactive in these patients. Others viewed the goiter as secondary to constant
anxiety and emotional unrest. In 1951, Hellwig proposed the colloidophagy theory, based on
rodent studies performed in the late 1920s and his own observations in humans that macro‐
phages exist in the thyroid gland and are capable of ingesting colloid. He postulated that
thyroid macrophages that have engulfed colloid degenerate and release colloid, which then
attracts lymphocytes into the thyroid. Finally, in the early 1950s, the field of autoimmunity
began to take shape; animal models were being developed in which injection of a tissue extract
was capable of reproducing a lymphocytic infiltration of that particular organ. This experi‐
mental approach was applied to the thyroid when, in 1956, lymphocytic infiltration of the
rabbit thyroid was induced by injection of rabbit thyroid extracts. The horror autotoxicus
dogma was dismantled and autoimmunity became recognized as an important mechanism of
disease. In the ensuing five decades, numerous studies have greatly expanded our under‐
standing of the pathogenesis of Hashimoto’s thyroiditis and helped translating research
findings into clinical practice. We have known since the mid-1980s that thyroperoxidase is a
dominant protein antigen targeted by the patient’s immune system in Hashimoto’s thyroiditis,
and, as a result, antibodies to thyroperoxidase are now considered the most sensitive and
specific biomarkers to establish this diagnosis. They also have a predictive value since their
presence precedes a clinical diagnosis of Hashimoto’s thyroiditis by at least 7 years. We have
also known since 1971 that Hashimoto’s thyroiditis, like other autoimmune diseases, has a
genetic basis. Substantial efforts have been devoted to identify the genes that predispose to
Hashimoto’s thyroiditis, but results have been less fruitful than expected. Genome-wide
association studies and candidate gene approaches have identified a handful of confirmed
susceptibility genes (MHC class II region, CTLA-4, PTPN22, and ARID5B), each making,
however, only a small contribution to the disease phenotype and through mechanisms that
remain to be discovered.
4. Susceptibility genes
4.1. Human leukocyte antigen (HLA) genes
The first gene locus identified in association with the autoimmune thyroid disease was major
histocompatibility complex (MHC) region on the chromosome 6p21 which encodes human
leukocyte antigens (HLAs). HLA region, which is highly polymorphic, comprises several
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immune response genes. HLA molecule, located on antigen presenting cell (APC), binds and
presents an antigenic peptide and in this way enables T cell recognition and response to an
antigen. Presumably, specific HLA alleles have a higher affinity for autoantigenic thyroidal
peptides and are thus likely to contribute to the development of the autoimmune thyroid
disease. Nevertheless, in order to initiate the thyroid autoimmunity autoantigen occurrence
within thyroid or thyroid draining lymph nodes is needed, being followed by HLA presenta‐
tion. In HT, aberrant expression of HLA class II molecules on thyrocytes has been demon‐
strated. Presumably, such thyrocytes may act as APCs capable of presenting the thyroid
autoantigens and initiating autoimmune thyroid disease. In Caucasians, associations of
different forms of HT with various HLA alleles were reported, including DR3, DR5, DQ7,
DQB1*03, DQw7 or DRB1*04-DQB1*0301 haplotype. In Japanese, associations with
DRB4*0101, HLA-A2 and DRw53 were demonstrated, while in Chinese patients association
with DRw9 was observed (Hawkins, Lam et al. 1987, Honda, Tamai et al. 1989, Badenhoop,
Schwarz et al. 1990, Tandon, Zhang et al. 1991, Bogner, Badenhoop et al. 1992, Wan, Kimura
et al. 1995, Hunt, Marshall et al. 2001, Petrone, Giorgi et al. 2001, Jacobson, Huber et al. 2008,
Zaletel and Gaberscek 2011).
4.2. Cytotoxic t lymphocyte antigen-4 (CTLA-4) gene
CTLA-4 gene, which is the second major immuneregulatory gene related to autoimmune
thyroid disease, lies on chromosome 2q33. The expression of CTLA-4 on the surface of T cells
induced by the activation of the T-cell receptor results in suppression of T-cell activation.
CTLA-4 gene polymorphisms may reduce expression or function of the CTLA-4 antigen and
may therefore contribute to the reduced inhibition of T-cell proliferation and subsequently
increase susceptibility to autoimmune response. In the past, several polymorphisms of the
CTLA-4 gene in HT patients were studied. Among them, the initially reported (AT)n micro‐
satellite CTLA-4 polymorphism in the 3’ untranslated region (UTR) was found to be associated
with HT in Caucasian and Japanese patients, but not in Italian population. In the exon 1 located
49A/G single nucleotide polymorphism (SNP), resulting in threonine to alanine substitution,
was associated with HT, however, certain other studies have not confirmed this observation.
A large meta-analysis, including both published and unpublished data of 866 HT patients,
indicated a significant association with 49A/G (summary OR 1.29; 95% CI, 1.11-1.50). Another
CTLA-4 polymorphism is 6230A/G SNP which is located at 3’-UTR and designated CT60.
Initial observation of the association with HT was not confirmed by later studies, however, the
results of the meta-analysis, based on six published and unpublished studies of 839 HT
patients, indicated a significant association with CT60 SNP (summary OR 1.64; 95% CI,
1.18-2.28). Nevertheless, the exact mechanism conferring the susceptibility to HT has not been
elucidated yet and further studies are needed to determine which CTLA-4 polymorphism is
causative.
4.3. Protein tyrosine phosphatase nonreceptor-type 22 (PTPN22) gene
PTPN22 is the most recently identified immuneregulatory gene associated with the autoim‐
mune thyroid disease, which is located on chromosome 1p13. PTPN22, which is predomi‐
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nantly expressed in lymphocytes, acts as a negative regulator of T-cell activation, much like
CTLA-4. 1858C/T SNP of the PTPN22 gene, resulting in arginine to tryptophan substitution at
codon 620 (R620W), was demonstrated to be a risk factor for many autoimmune diseases. The
mechanism is not clear since the disease predisposing T allele has been demonstrated to enable
even more efficient inhibition of T-cell activation. Presumably, weaker T-cell signalling may
lead to impaired thymic deletion of autoreactive T cells or an increased PTPN22 function may
result in inhibition of regulatory T cells (Tregs), which protect against autoimmunity. An early
study in HT patients demonstrated a significant association with 1858C/T SNP (OR 1.77; 95%
CI, 1.56-3.97). Afterwards, this observation was neither confirmed in German, Tunisian and
Japanese populations nor in Slovenian patients. In a small group of patients with both HT and
autoimmune diabetes, T allele was determined in 50% compared with only 14% in healthy
controls (OR 6.14; CI, 2.62-14.38), however, in a yet another study estimating the same
polymorphism this association was not confirmed. Recently, 5 other PTPN22 SNPs have been
tested in Japanese patients, showing no relation with HT, but a novel protective haplotype
containing those SNPs has been observed (Ban, Tozaki et al. 2005, Kahles, Ramos-Lopez et al.
2005, Chabchoub, Teixiera et al. 2009, Dultz, Matheis et al. 2009, Ban, Tozaki et al. 2010,
Kordonouri, Hartmann et al. 2010, Zaletel and Gaberscek 2011).
4.4. Thyroglobulin gene
Tg is an important thyroid specific antigen, also present in the circulation, which makes it an
easy target of the autoimmune response. Gene for Tg is located on the chromosome 8q24 and
linkage of this region with HT and autoimmune thyroid disease was first identified by a
Japanese and an American whole genome studies. A subsequent fine mapping of this region
exposed Tg gene as one of the major thyroid specific susceptibility genes, linked and associated
with the autoimmune thyroid disease. Later, different alleles of various microsatellite markers
and different SNPs of Tg gene were related to HT, possibly affecting its expression, antigenic‐
ity, iodination, or binding to HLA. The association of Tgms2 microsatellite marker in intron
27 with HT was confirmed in Japanese as well as in Caucasian population. Sequencing of
human Tg revealed 14 SNPs among which four SNPs, including exon 10-12 SNP cluster and
exon 33 SNP, were associated with HT. However, this observation was neither confirmed in
a larger data set of the United Kingdom Caucasian patients nor in Chinese population.
4.5. Vitamin D receptor gene
Vitamin D, which acts via vitamin D receptor (VDR), possesses immunomodulatory properties
and its deficiency has been implicated in the development of autoimmune diseases. Many
immune cells express VDR, dendritic cells in particular, where VDR stimulation has been
shown to enhance their tolerogenicity. Tolerogenic dendritic cells promote development of
Tregs with suppressive activity and therefore peripheral tolerance. VDR gene is located on the
chromosome 12q12 and its polymorphisms have been related to different autoimmune
disorders such as type 1 diabetes or Addison’s disease. A decade ago, the association between
VDR-FokI SNP in exon 2 and HT has been identified which was later confirmed in the
observation of Taiwanese Chinese patients. In the Croatian population VDR gene 3’ region
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polymorphisms were related to HT, possibly affecting VDR mRNA expression. A significant
relation has also been discovered between HT and both promoter and intron 6 gene polymor‐
phisms of CYP27B1 hydroxylase, which is located on chromosome 12q13, catalysing the
conversion of 25 hydroxyvitamin D3 to its active form.
4.6. Cytokine genes and other immune-related genes
Lately, several genes encoding different inflammatory cytokines have been studied in HT,
some of them also influencing the severity of the disease. Interferon (IFN)-γ, produced by T-
helper type 1 (Th1) cells, promotes cell mediated cytotoxicity which underlies thyroid
destruction in HT. T allele of the+874A/T IFN-SNP, causing the increased production of IFN-
γ, was associated with severity of hypothyroidism in HT patients. Higher frequency of severe
hypothyroidism was also observed in patients carrying CC genotype of-590C/T interleukin 4
(IL-4) SNP, leading to a lower production of IL-4, one of the key Th2 cytokines which sup‐
presses cell-mediated autoimmunity. Gene polymorphism of transforming growth fac‐
tor(TGF)-β, inhibitor of cytokine production, was also associated with HT. T allele of+369T/C
SNP, leading to a lower secretion of TGF-β, was more frequent in severe hypothyroidism than
in mild hypothyroidism. Similarly, more severe form of HT was associated with-2383C/T SNP
of gene for forkhead box P3 (FoxP3), an essential regulatory factor for the Tregs development.
Unlike the severity of hypothyroidism, the development of HT itself was associated with C
allele of tumor necrosis factor (TNF)--1031T/C SNP. Namely, C-allele carriers present with
higher concentration of TNF-which acts as the stimulator of the IFN-production.
5. Risk factors
5.1. Role of female sex and reproduction
5.1.1. Female sex
As indicated by numerous epidemiological studies, females present with positive thyroid
autoantibodies (TAbs) up to three times more often than males. The largest NHANES III study
has shown that females were positive for TPOAbs and TgAbs in 17% and 15.2%, respectively,
while males only in 8.7% and 7.6%, respectively. According to the estimation provided by the
study of Danish twins, the genetic contribution to TPOAb and TgAb susceptibility in females
was 72% and 75%, respectively, while in males it was only 61% and 39%, respectively. The
possible explanation for high female predominance in thyroid autoimmunity might be
associated with the X chromosome containing a number of sex and immune-related genes
which are of key importance in the preservation of immune tolerance. Increased immunor‐
eactivity might therefore be related to genetic defects of the X chromosome, such as structural
abnormalities or monosomy. Accordingly, a higher incidence of thyroid autoimmunity was
reported in patients with a higher rate of X chromosome monosomy in peripheral white blood
cells or in patients with Turner’s syndrome. Another potential mechanism of impaired
immunotolerance in females is skewed X-chromosome inactivation (XCI) leading to the escape
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of X-linked self-antigens from presentation in thymus with subsequent loss of T-cell tolerance.
Skewed XCI was associated with a higher risk of developing autoimmune thyroid diseases.
Recently reported frequencies of skewed XCI in HT were 31%, 34.3%, 25.6% and 20%, respec‐
tively, which is significantly higher than in healthy controls, where the prevalences were only
8%, 8%, 8.6% and 11.2%, respectively. Furthermore, a study of Danish twins demonstrated a
significant association of skewed XCI with TPOAb serum concentrations in dizygotic but not
in monozygotic twin pairs, indicating that shared genetic determinants of XCI pattern and
TPOAb production are more likely than causal relationship.
5.1.2. Pregnancy and postpartum period
The tolerance of the fetal semi-allograft during pregnancy is enabled by the state of immuno‐
suppression which is a result of hormonal changes and trophoblast expression of key immu‐
nomodulatory molecules. The pivotal players in regulation of the immune response are Tregs,
which rapidly increase during pregnancy. Consequently, both cell-mediated and humoral
immune responses are attenuated with a shift towards humoral immune response, resulting
in immune tolerance of the conceptus tissues and suppression of autoimmunity. Accordingly,
the decrease of both TPOAb and TgAb concentrations during pregnancy has been reported,
reaching the lowest values in the third trimester. Postpartum rapid decrease of Tregs and re-
establishment of the immune response to the pre-pregnancy state may lead to the occurrence
or aggravation of the autoimmune thyroid disease. The increase of TPOAb concentrations
occurred as soon as 6 weeks after delivery, reaching the baseline level at approximately 12
weeks and the maximum level at about 20 weeks after delivery. In up to 50% of females with
positive TPOAbs in the early pregnancy, thyroid autoimmunity in the postpartum period
exacerbates in the form of postpartum thyroiditis. It may occur within the first year after
delivery, usually clinically presented with transient thyrotoxicosis and/or transient hypothyr‐
oidism, while in about a third of females permanent hypothyroidism may even develop.
5.1.3. Fetal microchimerism
The term fetal microchimerism is defined by the presence of fetal cells in maternal tissues which
are transferred in the maternal circulation during pregnancy. Several years after the delivery,
the chimeric male cells can be detected in the maternal peripheral blood as well as in maternal
tissues, such as thyroid, lung, skin, or lymph nodes. The fetal immune cells, settled in the
maternal thyroid gland, may become activated in the postpartum period when the immuno‐
tolerance ceases, representing a possible trigger that may initiate or exaggerate the autoim‐
mune thyroid disease. In HT, fetal microchimeric cells were detected in thyroid in 28% to 83%
which means that their occurrence is significantly higher than in the absence of autoimmune
thyroid disease. Furthermore, a recent study of twins supported the putative role of micro‐
chimerism in triggering thyroid autoimmunity, showing a significantly higher prevalence of
TAbs in opposite sex twins compared to monozygotic twins. Additionally, euthyroid females
having been pregnant presented significantly more often with positive TPOAb compared to
females with no history of being pregnant. However, the relation between parity and autoim‐
mune thyroid disease was not confirmed by large population-based studies, advocating
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against the essential contribution of fetal microchimerism to the pathogenesis of autoimmune
thyroid disease.
6. Environmental triggers
6.1. Iodine intake
Excessive iodine intake is well-established environmental factor for triggering thyroid
autoimmunity. Several large population-based studies demonstrated higher prevalence of
TAbs in the areas with higher iodine supply since the estimated prevalence was approximately
13% in iodine deficiency, 18% in circumstances of sufficient iodine intake and about 25% in
areas with excessive iodine intake. Moreover, up to four-fold increase in prevalence of TAbs
was demonstrated after the exposure to higher iodine intake due to the improvement of iodine
prophylaxis in previously iodine deficient areas. According to the intervention study, delib‐
erate exposure to 500 μg of iodine provoked thyroid autoimmunity in 20% of previously
healthy individuals. Valuable evidence was also provided by using experimental animal
models of autoimmune thyroiditis, where the prevalence and severity of thyroid autoimmun‐
ity significantly increased when the dietary iodine was added (Kahaly, Dienes et al. 1998, Rose,
Bonita et al. 2002, Fountoulakis, Philippou et al. 2007, Golkowski, Buziak-Bereza et al. 2007,
Heydarian, Ordookhani et al. 2007).
Several putative mechanisms by which iodine may promote thyroid autoimmunity have been
proposed. Firstly, iodine exposure leads to higher iodination of Tg and thus increases its
immunogenicity by creating novel iodinecontaining epitopes or exposing cryptic epitopes.
This may facilitate presentation by APC and enhance the binding affinity of the T-cell receptor
which may lead to specific T cell activation. Secondly, iodine exposure has been shown to
increase the level of reactive oxygen species in the thyrocyte which is generated during TPO
oxidation of excessive amounts of iodine. They enhance the expression of the intracellular
adhesion molecule-1 (ICAM-1) on the thyroid follicular cells which could attract the immu‐
nocompetent cells into the thyroid gland. Thirdly, iodine toxicity to thyrocytes has been
reported, since highly reactive oxygen species may bind to membrane lipids and proteins,
causing thyrocyte damage and release of autoantigens. Fourthly, iodine excess has been shown
to promote follicular cell apoptosis by inducing an abnormal expression of tumor necrosis
factor-related apoptosis inducing ligand (TRAIL) and its death receptor (DR)-5 in thyroid.
Fifthly, in vitro evidence also suggests an enhancing influence of iodine on the cells of the
immune system, including augmented maturation of dendritic cells, increased number of T
cells and stimulated B-cell immunoglobulin production.
6.2. Drugs
Furthermore, certain drugs were reported to trigger or exacerbate thyroid autoimmunity in
susceptible individuals (Barbesino 2010, Hamnvik, Larsen et al. 2011). Interferon-α (IFN-α) is
extensively used to treat chronic hepatitis and is frequently associated with thyroid autoim‐
munity since TAbs were observed in up to 40% and clinical disease in 5-10% of patients treated
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with IFN-α. Presumably, IFN-α has both thyroid toxic effects with consequent autoantigen
presentation and immune effects, such as switching to Th1 immune response, suppression of
Treg function, activation of immune cells, stimulation of cytokine release and expression of
MHC class I on thyroid cells. Similarly, IL-2 treatment, used for melanoma and renal carcino‐
ma, seems to act via immune and toxic mechanisms, leading to both TAb positivity and
hypothyroidism.
In patients with known autoimmune thyroid disease lithium may increase the risk of hypo‐
thyroidism. According to some studies, treatment with lithium has also been shown to increase
TAb titres and the prevalence of thyroid autoimmunity. Among putative mechanisms direct
toxicity of lithium on thyroid or toxicity of increased intrathyroidal iodine resulting from
lithium treatment were discussed. Similarly, amiodarone alone as well as its high iodine
content may act cytotoxically which may lead to thyroid autoantigen presentation and provoke
thyroid autoimmunity.
More recently, some small molecule tyrosine kinase inhibitors (TKIs) used for the treatment
of metastatic renal cell carcinoma (Muriel, Esteban et al. 2010, Kollmannsberger, Bjarnason et
al. 2011, Eisen, Sternberg et al. 2012, Mendez-Vidal, Martinez Ortega et al. 2012, Bianchi, Rossi
et al. 2013), gastrointestinal stromal tumours (Joensuu, Trent et al. 2011), thyroid carcinoma
and pancreatic neuroendocrine tumours have been shown to cause hypothyroidism related
symptoms to a variable extent, which can reduce a patient’s quality of life (Torino, Corsello et
al. 2009, Zygulska, Krzemieniecki et al. 2012). Sunitinib and sorafenib are multitargeted TKIs
that have been demonstrated to induce hypothyroidism and thyroid dysfunction. The reported
incidence of sunitinib-induced hypothyroidism is 53-85% and 36-46% in retrospective or
prospective studies, respectively, and 18% in patients treated with sorafenib (Torino, Corsello
et al. 2009). Mechanisms of hypothyroidism induced by TKIs include drug-induced atrophy
of the thyroid through inhibition of its vascularization, drug-induced thyroiditis, reduced
synthesis of thyroid hormones, progressive depletion of the thyroid’s functional reserve and
inhibition of the thyroidal iodine uptake (Torino, Corsello et al. 2009). Makita et al (Makita and
Iiri 2013) and Bianchi et al (Bianchi, Rossi et al. 2013) thought that sunitinib may exert these
effects via multiple receptor tyrosine kinases, including vascular endothelial growth factor
receptor (VEGFR) and the platelet-derived growth factor receptor (PDGFR). In patients treated
with sunitinib or sorafenib, routine thyroid function testing at baseline and measurement of
TSH on day 1 at the start of every new treatment cycle is recommended. Levothyroxine is the
standard treatment for overt hypothyroidism and is recommended in some patients with
subclinical hypothyroidism; overt or subclinical hypothyroidism per se does not justify the
withdrawal of TKI therapy. Thyroid function test should be included in routine toxicity
assessment of TKIs under clinical evaluation (Torino, Corsello et al. 2009, Hamnvik, Larsen et
al. 2011, Eisen, Sternberg et al. 2012); however, the clinical relevance of early diagnosis of
hypothyroidism in patients with TKIs is still controversial.
6.3. Infections
Not only the IFN-α treatment but also hepatitis C infection itself has been reportedly associated
with thyroid autoimmunity and hypothyroidism. Among possible mechanisms, the molecular
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mimicry between viral and selfantigens has been suggested, whereas the release of proin‐
flammatory mediators caused by viral infection may lead to activation of autoreactive T-cells.
Besides, in HT several other putative triggering viruses have been implicated such as parvo‐
virus, rubella, herpes simplex virus, Epstein Barr virus, and human T-lymphotropic virus type
1. A recent study of sera in pregnant women has also indicated an association between a prior
infection with Toxoplasma gondii and an increase of TPOAbs. Nevertheless, the evidences are
scarce and further studies are required in order to confirm the role of infections as causative
agents.
6.4. Chemicals
The exposure to environmental toxicants such as polyaromatic hydrocarbons or polyhalogen‐
ated biphenyls, both commonly used in a variety of industrial applications, has been shown
to provoke thyroid autoimmunity not only in experimental animals but also in humans.
Recently, a significantly higher prevalence of HT and TAb (9.3% and 17.6%, respectively) has
been demonstrated in residents living in the area of petrochemical complex of Sao Paolo
compared to the control area (3.9% and 10.3%, respectively). In Slovakia, the exposure to
polychlorinated biphenyls was associated with TAb and hypothyroidism. Although there is
strong evidence attesting the contribution of chemicals to thyroid autoimmunity, the exact
mechanisms of their action are yet to be established (Langer, Tajtakova et al. 2007, de Freitas,
Grimaldi Campos et al. 2010).
7. Hashimoto’s thyroiditis and papillary thyroid carcinoma
There has long been a controversy in the literature about a possible link between HT and PTC.
Conflicting reports continue to emerge. Some suggest a positive correlation between the two,
and even a cause-and-effect relationship, whereby the activated inflammatory response
present in HT creates a favorable setting for malignant transformation. The inflammatory
response may cause DNA damage through formation of reactive oxygen species, resulting in
mutations that eventually lead to the development of PTC. Nevertheless, it remains unclear
whether: (1) HT predisposes patients to develop PTC, (2) HT is an incidental finding with
concurrent PTC, or (3)HT is a part of the host tumor response system. A meta-analysis done
by Jankovic (McLeod, Watters et al. 2012, Jankovic, Le et al. 2013) revealed significant differ‐
ences in the prevalence and the risk ratio of PTC in HT specimens obtained via FNAB vs
thyroidectomy.
In population based studies where the specimens were obtained from FNAB, the average
prevalence of PTC in patients with HT was 1.20%, with an average risk ratio of 0.69. Con‐
versely, in studies from archival thyroidectomy specimens, the average prevalence and risk
ratio were as high as 27.56% and 1.59, respectively. This variability could be a result of different
methods of obtaining specimens and heterogeneity in the population under investigation in
terms of ethnic, geographic, and gender differences.
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The prevalence and the risk ratio of PTC in patients with HT compared to those without HT
are significantly higher in studies of thyroidectomy specimens, compared to studies of patients
undergoing FNAB. In studies that mentioned the indications, thyroidectomy was reserved for
patients not responding to thyroid suppression therapy, those with symptoms of compression,
worrisome or inconclusive FNA cytology, and historic or physical findings warranting further
workup and treatment (e.g., irradiation, nerve paralysis, pain, or cervical lymph node
enlargement). It should be noted that the vast majority of patients with HT do not require
surgery. Hence, the patients who require thyroidectomy are already at higher risk for malig‐
nancy compared to the general population with HT.
There have been a number of proposed hypotheses to explain the linkage between the two
diseases. From a histological perspective, Tamimi (Tamimi 2002) assessed the prevalence and
severity of thyroiditis among three types of surgically resected thyroid tumors and found a
significantly higher rate of lymphocytic infiltrate in patients with PTC. However, PTC with
concurrent HT is associated with female gender, young age, less aggressive disease such as
small tumor size, less frequent capsular invasion and nodal metastasis, and better prognosis.
Furthermore, these patients are also less likely to develop recurrence and have a higher
survival rate In the study by Eisenberg et al(Eisenberg and Hensley 1989), none of the patients
with a thyroid carcinoma and HT developed relapse or metastases after 74 months of follow-
up. Kebebew (Kebebew, Treseler et al. 2001) demonstrated that CLT correlates with improved
survival in patients with PTC but is not an independent prognostic factor. Boi et al investigated
the relationship between thyroid autoimmunity and thyroid cancer in a series of FNAB of
unselected and consecutive thyroid nodules. This study revealed that the positive predictive
values for thyroid carcinoma in antithyroid antibody-positive and –negative nodules are not
statistically significant for class III (indeterminate risk) and class IV (suspected malignancy)
cytology. It should be noted that it is important to distinguish between diffuse vs focal
lymphocytic infiltration around the tumor. In the studies that described the histological
findings, HT was defined as diffuse lymphocytic infiltration, rather than peritumoral lym‐
phocytic infiltration alone. The significance of this is that HT does not represent a reaction to
tumor alone but is an independent chronic process. In chronic inflammation, there are reactive
alterations of stroma brought on by injury from chemokines, cytokines, and growth factors
that cause damage to stromal cells. This in turn may cause malignant transformation in
epithelial cells, thereby resulting in tumor development. In contrast, the lymphocytic infiltrate
of HT may be an immunological response with a cancer-retarding effect, contributing to a
favorable outcome of PTC compared to other thyroid cancers. Moreover, the relatively high
prevalence of PTC in autopsy series may represent host immune control. Interestingly,
lymphocytic infiltration within or surrounding the tumor was found to correlate with the
existence of CLT. This may explain the “protective” effect of CLT in PTC.
Another hypothesis for the causal relationship between HT and PTC is that elevated levels of
TSH found in hypothyroid patients with HT stimulate follicular epithelial proliferation,
thereby promoting the development of papillary carcinoma (Jankovic, Le et al. 2013). McLeod
et al (McLeod, Watters et al. 2012) conducted a systemic review that included 5786 thyroid
cancer cases in 43 032 subjects and found that serum TSH confers a greater likelihood of
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development of thyroid cancer (odds ratio 1.87–2.83, depending on the level of TSH). A subset
of studies that was adjusted for autoimmune thyroiditis did not find this relationship between
TSH and heightened odds ratio for thyroid cancer. Conversely, several authors identified a
few biomolecular markers, including RET/PTC rearrangements, p63 protein, and loss of
heterozygosity of hOGG1, that are potentially involved in neoplastic transformation from HT
to PTC. So far, no causal genetic linkage has been confirmed.
In conclusion, the existing data provide inconsistent evidence favoring a causal relationship
between HT and PTC. Population-based studies using FNAC show no significant increase of
PTC in patients with HT, whereas surgical series using thyroidectomy show a heightened risk
for coexistent PTC, possibly related to selection bias. Prospective studies involving a large
number of subjects and long-term follow-up are needed to further elucidate the relationship.
Several studies also suggest that HT appears to confer a better prognosis in patients with PTC,
but more research is necessary to further investigate this. At the present time, there is no valid
established criterion to identify those patients with HT at a higher risk of developing PTC.
Careful observation and follow-up of HT patients is recommended, especially those with
nodular variants.
8. Laboratory tests
Elevated anti-TPO or anti-Tg antibody titers are the most specific laboratory findings to
establish the diagnosis of autoimmune thyroid disease (AITD) or HT, typically making biopsy
unnecessary. The 24-hours thyroid radioactive iodine-123 or-131 (123I or 131I) uptake (RIU) is
also helpful to distinguish Hashitoxicosis from Graves’ disease (GD); the RIU is low in patients
with Hashitoxicosis, whereas it is elevated in those with GD. 123I is preferred than 131I because
it has a shorter half-life (13 hours for 123I, 8 days for 131I) allowing quicker dissipation of
background radiation. Since radioactive iodine is secreted in breast milk, and 123I has a short
half-life, it is recommended for diagnostic thyroid studies in nursing mothers. Breast milk must
be pumped and discarded for 2 days after the intake of 123I either used for thyroid uptake or
for thyroid scanning.
Scintigraphy reveals in-homogeneous activity throughout the gland in 50% and a pattern
suggestive of either hot or cold nodules or a combination of both in 30% of patients. Twenty
percent of patient with HT have normal findings at the scintigraphic thyroid imaging.
9. Clinical pictures
Clinical manifestations of HT are variable and commonly include diffuse or nodular goiter
with euthyroidism, subclinical hypothyroidism which shows a combination of elevated serum
TSH concentrations and normal free T4 and T3 concentrations and permanent hypothyroid‐
ism. Not often, HT causes acute destruction of thyroid tissue and release in blood of stored
thyroid hormones, causing transient thyrotoxicosis. This condition has been termed “Hashi‐
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toxicosis” or “painless sporadic thyroiditis”, or “painless postpartum thyroiditis” when occurs
in women after delivery. In Hashitoxicosis serum TSH is suppressed, and total and free T3 and
T4 are elevated. Also, serum T4 is proportionally higher than T3, reflecting the ratio of stored
hormones in the thyroid gland, whereas in GD and in toxic nodular goiter, T3 is preferentially
elevated. Rarely, a hypofunctioning gland in HT may become hyperfunctioning with the onset
of coexistent GD. In patients with GD, HT is usually present concurrently.
10. Treatment
If overt hypothyroidism is present, the treatment of choice for HT is the administration of L-
thyroxine (L-T4) in the usual replacement doses. We also use L-T4 to treat patients with HT
subclinical hypothyroidism and high serum thyroid antibody concentrations, because in these
cases a progression to overt hypothyroidism is common and hyperlipidemia and atheroscler‐
otic heart disease may develop. L-T4 may mildly and indirectly suppress serum concentrations
of autoantibodies due to decreased stimulation of thyroid tissue by TSH and causing reduction
of antigenic production. The goal of treatment is to restore clinically and biochemically an
euthyroid state. For that, free T4 levels must be within the reference range and TSH at the lower
half of the reference range. The usual dose of L-T4 is 1.6-1.8 μg/kg per day and is patient
dependent. Elderly patients usually require a smaller dose of L-T4, sometimes less than
1μg/kg per day. The initial dose and the optimal time needed to establish the full replacement
dose as above should be individualised relative to age, weight and cardiac status.
In HT patients with a large goiter and normal or elevated serum TSH, we think, L-T4 may be
given in doses sufficient to suppress serum TSH in an effort to shrink the thyroid theoretically,
although randomized studies are needed to verify the long term safety of this method
concerning the potential cardiovascular and skeletal side effects. Suppressive doses of L-T4
tend to shrink the goiter by average of 30% over 6 months. If the goiter does not regress, the
L-T4 doses are lowered. Goiters that are hard and fibrotic do not respond to L-T4 treatment.
If the thyroid gland is only minimally enlarged, the patient is euthyroid and TSH levels are
normal, the patient should remain under medical supervision, since hypothyroidism may
often develop years later. Also, patients should be informed about the importance of compli‐
ance with replacement treatment and instructed to report any symptoms suggesting hyper‐
thyroidism that could be due to an overdosage of L-T4. The intake of L-T4 should be apart by
at least 4 hours from other drugs like calcium carbonate, ferrous sulfate, cholestyramine,
sucralfate, iron-containing multivitamins, antacids containing aluminum hydroxide, pheny‐
toin sodium, carbamazepine and amiodarone HCL, all of which impair the absorption/
metabolism of L-T4.
Selenium (Se) supplementation in patients with AITD, including HT, seems to modify the
inflammatory and immune responses, probably by enhancing plasma glutathione peroxidase
(GPX) and thioredoxin reductase (TR) activity and by decreasing toxic concentrations of
hydrogen peroxide (H2O2) and lipid hydroperoxides, resulting from thyroid hormone
synthesis. When Se intake is adequate the intracellular GPX and TR systems protect the
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thyrocyte from these peroxides, considering that oxidative stress induces TR1 and GPX. The
current recommended dietary intake of selenium in humans to achieve the maximal activity
of GPX in plasma or in erythrocytes is between 55 and 75μg per day. It must be considered
that organic forms of Se such as Se-methionine and yeast-bound Se, have a much lower toxicity
and a much higher effectiveness and safety than inorganic Se like sodium selenate. Several
studies have revealed a significant reduction of anti-TPO concentrations in patients with AITD
treated with 200 μg Se per day for three, six, or nine months (Gartner, Gasnier et al. 2002,
Duntas, Mantzou et al. 2003, Gartner and Gasnier 2003, Turker, Kumanlioglu et al. 2006,
Mazokopakis and Chatzipavlidou 2007). Duntas et al. found an overall decrease of 46% of
AITD at 3 months (P<0.0001) and of 55.5% at 6 months (P<0.05) of treatment with L-seleno‐
methionine plus L-T4. Others found a decrease of 26.2% at 3 months (P<0.001) and an addi‐
tional 23.7% at 6 months (P<0.01) after L-Se-methionine treatment. A significant decrease in
the mean serum anti-TPO levels was also noted after the daily intake of 200 μg sodium selenite
for 3 months. This decrease amounted to 36.4% in the selenium-taking group of patients versus
12% in the control group (P=0.013) (Gartner, Gasnier et al. 2002). A recent study in 80 Greek
women with HT showed a significant reduction of serum anti-TPO levels during the first 6
months of L-Se-methionine treatment (P<0.0001). Anti-TPO decreased by 5.6% and by 9.9%
after 3 and 6 months of L-Se-methionine treatment, respectively. The extension of L-Se-
methionine supplementation for 6 more months resulted in an additional 8% decrease, while
cessation of treatment resulted to a 4.8% increase, in the anti-TPO concentrations.
A systematic review and meta-analysis done by Toulis (Toulis, Anastasilakis et al. 2010)
provided evidence that selenomethionine at a dose of 200 mg once per day is effective in
reducing TPOAb titers in patients with HT after a 3-month period, compared with placebo. In
absolute numbers, this reduction equals ~300 IU/mL. Efficacy of Se supplementation for >3
months could not be supported, because of lack of evidence from randomized, placebo
controlled trials. Patients assigned to Se supplementation had also a threefold higher chance
of reporting an improvement in well-being and/or mood, compared with controls. No serious
adverse effects were recorded after Se supplementation, with the exception of a limited number
of gastric discomfort complaints associated with selenomethionine use. In general, there are
no data demonstrating that Se treatment had any impact on the natural course of the disease.
Further controlled and extensive studies are needed to clarify the exact mechanisms by which
Se exerts effects on anti-TPO production, and investigate the long-term clinical effects of Se
treatment.
In a study involving 21 patients with HT and subclinical hypothyroidism, simvastatin in a
daily dose of 20 mg orally for a period of eight weeks improved thyroid function inducing an
increase in serum free T3 and free T4 levels and a decrease in TSH levels. Decreases in anti-
TPO and anti-Tg antibodies were not statistically significant, possibly by stimulating apoptosis
of certain types of lymphocytes. Further controlled and extensive studies are needed to
investigate the effectiveness of statins treatment on the course of HT.
Patients with Hashitoxicosis may have only mild thyrotoxicosis and may not require treat‐
ment. Antithyroid drug treatment with thiourea drugs is contraindicated, because there is no
excess of thyroid hormone production. Patients who have more symptoms should have a 24-
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hours thyroid RIU test and a radioiodine scan to determine whether GD may be present and
may be treated with beta-blockers. In symptomatically thyrotoxic patients with low thyroid
123I uptake test, propranolol treatment is continued and sodium ipodate or iopanoic acid may
also be given in doses of 500 mg daily orally, until the patient is euthyroid. Sodium ipodate
and iopanoic acid are known iodinated contrast oral cholecystographic agents that inhibit
peripheral 5’-monodeiodination of thyroxine, thereby blocking its conversion to active T3.
Patients having low thyroid RIU do not respond to thiourea medication.
Patients with HT and a large goiter with pressure symptoms such as dysphagia, voice
hoarseness, stridor and respiratory distress, may require surgical care. Also, in HT the presence
of a malignant nodule or of a thyroid lymphoma diagnosed by histology after a fine-needle
aspiration is an absolute indication for thyroidectomy.
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